Hereditary cancer syndrome diagnosis: Molecular genetic clues and cancer control

Future Oncology

Volumn 3, Issue 2, 2007, Pages 169-181

  Lynch, Henry T ^a   Fusaro, Ramon M ^a   Lynch, Jane F ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CDKN2A mutation; Cetuximab; Erlotinib; Familial atypical multiple mole melanoma; Familial atypical multiple mole melanoma syndrome; Hereditary cancer; Lynch syndrome; Melanoma; Monoclonal antibodies; Pancreatic cancer

Indexed keywords

BCR ABL PROTEIN; BEVACIZUMAB; BRCA1 PROTEIN; CETUXIMAB; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMATINIB; IRINOTECAN; OXALIPLATIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; AWARENESS; BREAST CANCER; CANCER CLASSIFICATION; CANCER CONTROL; CANCER GENETICS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL NEVUS; DIAGNOSTIC ACCURACY; DRUG EFFICACY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENZYME INHIBITION; FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA SYNDROME; FAMILIAL CANCER; FAMILY HISTORY; GENE MUTATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEALTH PROGRAM; HUMAN; MEDICAL SPECIALIST; MELANOMA; MISMATCH REPAIR; MOLECULAR GENETICS; MYELOID LEUKEMIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MANAGEMENT; DISEASE PROGRESSION; DYSPLASTIC NEVUS SYNDROME; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR BIOLOGY; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; PANCREATIC NEOPLASMS;

EID: 34247135358     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.2.169     Document Type: Article

References (69)

1. Albano WA, Lynch HT, Recabaren JA et al.: Familial cancer in an oncology clinic. Cancer 47, 2113-2118 (1981).
2. Guttmacher AE, Collins FS, Carmona RH: The family history-more important than ever. N. Eng. J. Med. 351, 2333-2336 (2004).
3. Warson P, Narod SA, Fodde R et al.: Carrier risk status changes resulting from mutation testing in hereditary nonpolyposis colorectal cancer and hereditary breast-ovarian cancer. Am. J. Hum. Genet. 40, 591-596 (2003).
4. Lynch HT, Brand RE, Hogg D et al.: Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical multiple mole melanoma-pancreatic carcinoma syndrome. Cancer 94, 84-96 (2002).
5. Safer v. The Estate of Pack, 677 A. 2d 1188 (1996).
6. Lynch PM, Lynch HT, Harris RE: Hereditary proximal colonic cancer. Dis. Colon Rectum 20, 661-668 (1977).
7. Lynch HT, Boland CR, Gong G et al.: Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur. J. Hum. Genet. 14, 390-402 (2006).
8. Lynch HT, de la Chapelle A: Genetic susceptibility to non-polyposis colorectal cancer. J. Med. Genet. 36, 801-818 (1999).
9. Lynch HT, de la Chapelle A: Genomic medicine: hereditary colorectal cancer. N. Engl. J. Med. 348, 919-932 (2003).
10. Watson P, Lynch HT: Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71, 677-685 (1993).
11. Vasen HFA, Mecklin J-P, Meera Khan P, Lynch HT: The International Collaborative Group on hereditary nonpolyposis colorectal cancer (ICG-HNPCC). Dis. Colon Rectum 34, 424-425 (1991).
12. Vasen HFA, Watson P, Mecklin J-P, Lynch HT: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116, 1453-1456 (1999).
13. Laghi L, Bianchi P, Roncalli M, Malesci A: Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl Cancer Inst. 96, 1402-1403 (2004).
14. Lindor NM, Rabe K, Petersen GM et al.: Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293, 1979-1985 (2005).
15. Järvinen HJ, Aarnio M, Mustonen H et al.: Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118, 829-834 (2000).
16. Lynch HT, Fusaro RM, Albano WA, Pester J, Kimberling WJ, Lynch JF: Phenotypic variation in the familial atypical multiple mole-melanoma syndrome (FAMMM). J. Med. Genet. 20, 25-29 (1983).
17. Goldstein AM, Chan M, Harland M et al.: High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 66, 9818-9828 (2006).
18. Miller AJ, Mihm MC Jr: Mechanisms of disease: melanoma. N. Engl. J. Med. 355, 51-65 (2006).
19. American Cancer Society: Cancer Facts & Figures. Atlanta, GA, USA (2003).
20. Curtin JA, Fridlyand J, Kageshita T et al.: Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147 (2005).
21. Alonso SR, Ortiz P, Pollan M et al.: Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am. J. Pathol. 164, 193-203 (2004).
22. Lowenfels AB, Maisonneuve P, Whitcomb DC: International Hereditary Pancreatitis Study Group: risk factors for cancer in hereditary pancreatitis. Med. Clin. North Am. 84, 565-573 (2000).
23. Ghadirian P, Lynch HT, Krewski D: Epidemiology of pancreatic cancer: an overview. Cancer Detect. Prev. 27, 87-93 (2003).
24. Soliman, AS, Zhang Q, Saleh T et al.: Pancreatic cancer mortality in Egypt: comparison to the United States pancreatic cancer mortality rates. Cancer Detect. Prev. 30, 473-479 (2006).
25. Masback A: Clinial and histopathological features of malignant melanoma in germline CDKN2A mutation families. Melanoma Res. 12, 549-557 (2002).
26. Puig S: Role of the CDKN2A locus in patients with multiple primary melanomas. J. Clin. Oncol. 23, 3043-3051 (2005).
27. Chaudru V: Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J. Natl Cancer Inst. 96, 785-795 (2004).
28. Ghiorzo P: INK4/ARF germline alterations in pancreatic cancer patients. Ann. Oncol. 15, 70-78 (2004).
29. Bartsch DK, Sina-Frey M, Lang S et al.: CDKN2A germline mutations in familial pancreatic cancer. Ann. Surg. 236, 730-737 (2002).
30. Pogue-Geile KL, Chen R, Bronner MP et al.: Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med. 3, E516 (2006).
31. Eberle MA, Pfützer R, Pogue-Geile KL et al.: A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34. Am. J. Hum. Genet. 70, 1044-1048 (2002).
32. Otey CA, Rachlin A, Moza M, Arneman D, Carpen O: The palladin/myotilin/ myopalladin family of actin-associated scaffolds. Int. Rev. Cytol. 246, 31-58 (2005).
33. Pozo L, Naase M, Cerio R, Blanes A, Diaz-Cano SJ: Critical analysis of histologic criteria for grading atypical (dysplastic) melanocytic nevi. Am. J. Clin. Pathol. 115, 194-204 (2001).
34. Barnhill RL: Current status of the dysplastic melanocytic nevus. J. Cutan. Patho. 18, 147-159 (1991).
35. Pehamberger H, Steiner A, Wolff K: In vivo epiluminescence microscopy of pigmentary skin lesions. J. Am. Acad. Dermatol. 17, 571-583 (1987).
36. Haenssle HA, Kreeger U, Vente C et al.: Results from observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. J. Invest Dermatol. 126, 980-985 (2006).
37. Kittler H, Pehamberger H, Wolff K, Binder M: Diagnostic accuracy of dermoscopy. Lancet Oncol. 3, 159-165 (2002).
38. Bafounta M-L, Beauchet A, Aegerter P, Saiag P: Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Arch. Dermatol. 137, 1343-1350 (2001).
39. Malvehy J, Puig S: Follow-up of melanocytic skin lesions with digital total-body photography and digital dermoscopy: a two-step method. Clin. Dermatol. 20, 297-304 (2002).
40. Parker JF, Florell SR, Alexander A, Discafani CM, Shami PJ, Leachman SA: Pancreatic carcinoma surveillance in patients with familial melanoma. Arch. Dermatol. 139, 1019-1025 (2003).
41. Brand R: The diagnosis of pancreatic cancer. Cancer J. 7, 287-297 (2001).
42. Saisho H, Yamaguchi T: Diagnostic imaging for pancreatic cancer: computed tomography, magnetic resonance imaging, and positron emission tomography. Pancreas 28, 273-278 (2004).
43. Murr MM, Sarr MG, Oishi AJ, Heerden JA: Pancreatic cancer. CA Cancer J. Clin. 44, 304-318 (1994).
44. Niederau C, Grendell JH: Dignosis of pancreatic carcinoma: imaging techniques and tumor markers. Pancreas 7, 66-86 (1992).
45. Aliperti G: Complications related to diagnostic and therapeutic endoscopic retrograde cholangiopancreatography. Gastrointest. Endosc. Clin. North Am. 6, 379-407 (1996).
46. Yasuda K, Mukai H, Nakajima M: Endoscopic ultrasonography diagnosis of pancreatic cancer. Gastrointest. Endosc. Clin. North Am. 5, 699-712 (1995).
47. DeWitt J, Devereaux B, Chriswell M et al.: Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann. Intern. Med. 141, 753-763 (2004).
48. Cameron JL, Tiall TS, Coleman J, Belcher KA: One thousand consecutive pancreaticoduodenenectomies. Ann. Surg. 244, 10-15 (2006).
49. Drevs J: Drug discovery: a historical perspective. Science 287, 1960-1964 (2000).
50. Romond EH, Perez EA, Bryant J et al.: Trastuzmab plus adjuvant chemotherapy for operable HER-2 positive breast canoer. N. Engl. J. Med. 353, 1673-1684 (2005).
51. Hess G, Bunjes G, Siegert W et al.: Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective Phase II open-label multicenter study. J. Clin. Oncol. 23, 7583-7593 (2005).
52. Druker BJ, Tamura S, Buchdunger E et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Genet. 2, 561-566 (1996).
53. Kindler HL, Friberg G, Singh DA et al.: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 23, 8033-8040 (2005).
54. Danson S, Lorigan P: Improving outcomes in advanced malignant melanoma: update on systemic therapy. Drugs 65, 733-643 (2005).
55. Patel PH, Chadalavada RSV, Chaganti RSK, Motzer RJ: Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin. Cancer Res. 12, 7215-7220 (2006).
56. Carethers JM, Dharam PC, Fink D et al.: Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117, 123-131 (1999).
57. Jacob S, Aguado M, Fallik D, Praz F: The role of the DNA mismatch repair system in the cytotoxicityy of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res. 61, 6555-6562 (2001).
58. Green MR: Targeting targeted therapy. N. Engl. J. Med. 350, 2191-2193 (2000).
59. Carethers JM, Smith EJ, Behling CA et al.: Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126, 394-401 (2004).
60. Marshall J: Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107, 1207-1218 (2006).
61. Kefford RF, Newton J, Bishop N, Bergman W, Tucker MA: Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the melanoma genetics consortium. J. Clin. Oncol. 17, 3245-3251 (1999).
62. Kefford R, Bishop JN, Tucker M et al.: Genetic testing for melanoma. Lancet Oncol. 3, 653-654 (2002).
63. Kefford RF, Mann GJ: Is there a role for gerietic testing in patients with melanoma? Curr. Opin. Oncol. 15, 157-161 (2003).
64. de Snoo FA, Bergman W, Gruis NA: Familial melanoma: a complex disorder leading to controversy on DNA testing. Fam. Cancer 2, 109-116 (2003).
65. Ganz PA, Kwan J, Somerfield MR et al.: The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members. J. Clin. Oncol. 24, 2948-2957 (2006).
66. Epstein CJ: Medical genetics in the genomic medicine of the 21st century. Am. J. Hum. Genet. 79, 434-438 (2006).
67. Lynch HT: Family Information Service and hereditary cancer. Cancer 91, 625-628 (2001).
68. Kaelin WG Jr: The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin. Cancer Res. 10, 6290S-6295S (2004).
69. Yee NS, Furth EE, Pack M: Clinicopathologic and molecular features of pancreatic adenocarcinoma associated with Peutz-Jeghers syndrome. Cancer Biol. Ther. 2, 38-47 (2003).